Navigation Links
Specialty European Pharma launches plenaxis in Germany
Date:2/26/2008

London, 26 February. Speciality European Pharma (SEP) today announced the launch of Plenaxis® in Germany. Plenaxis® is used to treat advanced and metastatic hormone responsive prostate cancer and it causes a rapid and sustained decline in testosterone levels, thereby giving quick control of prostate cancer symptoms. Once the disease is under control, the physician can choose to either keep the patient on Plenaxis® or to stop treatment and recommence once there is evidence of disease activity returning. This is attractive because, on stopping treatment with Plenaxis® the patients testosterone levels will return to the normal range whilst the disease remains under control. In addition to the quick control of testosterone, Plenaxis avoids any testosterone flare and removes the need for concomitant use of anti-androgen therapy.

Commenting on the launch of Plenaxis®, Geoff McMillan, the CEO of SEP, said, Plenaxis® is an important product, both for SEP and for sufferers of prostate cancer. Plenaxis is the first new type of hormone treatment for prostate cancer to be introduced for many years and it gives patients and physicians added control of this disease.

Ken Watters, Chief Medical Officer of SEP added that prostate cancer is an important cause of morbidity and mortality in males over 50 years old. The emerging treatment modalities are especially suited to Plenaxis® with its rapid and sustained disease control and quick testosterone recovery.


'/>"/>

Contact: Blake Scotland
bscotland@ruderfinn.co.uk
020-746-28975
Ruder Finn Public Relations
Source:Eurekalert

1

GOOD

Page: 1

Related medicine news :

1. Darwin Enters into Marketing Partnership with Agency Specialty Product Network
2. MarketResearch.com Distributes Key Findings on Global Specialty Medical Beds and Therapeutic Surfaces Market
3. Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise
4. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
5. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
6. Specialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.
7. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
8. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
9. Albemarle Raises Prices of Specialty Aluminas
10. Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise
11. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...r an Injunction in Federal Court to Reclaim Overti...swire-USNewswire/ -- Registered nurses for Riversi... Medical Center, filed a Fair Labor Standards Act ...y to stop the county from violating federal law go... are seeking to represent all 867 registered nurse...
(Date:12/2/2008)...ire-USNewswire/ -- Are you unhappy with your smile... are available? , , The Pennsylvania Dental...metic options exist to improve your smile. Your de...tory to determine a suitable option to help restor...tic dental options. , , , , To...
(Date:12/2/2008)...edical Center ranks No. 1 nationwide for the speed...g balloon angioplasty, according to the National C... (Vocus) December 2, 2008 -- UCSF Medi...th which heart attack patients are treated using b...iovascular Data Registry (NCDR). Cardiac balloon ...
(Date:12/2/2008)...Breast-Specific Gamma Imaging (BSGI) has,been pro... the diagnosis of,invasive lobular carcinoma (ILC... a molecular breast imaging technique that can see...er very early stage cancers. When compared to,mam...g (MRI), BSGI has the,greatest sensitivity for de...
Breaking Medicine News(10 mins):Health News:Riverside County Registered Nurses File a Lawsuit to Stop County's Violation of Federal Law 2Health News:Cosmetic Dentistry: A Beautiful Smile Is Not Far Away 2Health News:UCSF Medical Center Leads Nation in ER Heart Attack Care 2Health News:UCSF Medical Center Leads Nation in ER Heart Attack Care 3Health News:Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma 2
...can make a difference. //Three-quarters of physici...a new study says they could be wrong. The new rese...ve at relieving back pain. Physicians often get f...pe of bed is best for their lower back pain. Few s...
...he Commonwealth's restaurants, taverns, and nightc...liquor-store sales as the House and Senate conclud.../ Working until nearly midnight, lawmakers also ap...to spur shoppers to spend more, thereby pumping up...
...t on a bill that would a prescription drug benefit...the politically popular entitlement program in its...lined up in our favor," House Speaker Dennis Haste...erence in the Capitol. "The time is upon us. It's ...
...arin in reducing stroke among people with an irreg...rug ximelagatran appears to be as effective as war...ople at high risk of stroke because of its blood t...he drawbacks of warfarin include an increased risk...
Other Medicine News:Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4Health News:House heads for Medicare drug vote, 2Health News:House heads for Medicare drug vote, 3
(Date:12/1/2008)...te Ltd today announced the initiation of a Phase 1...ctive JAK2 inhibitor, in leading medical centers i...yelofibrosis (CIMF). , , The trial is desi...1518 in patients with CIMF and is expected to enro...y will assess the safety profile and evaluate the ...
(Date:12/1/2008)...ith ENB-0040 at Children,s Hospital, Health Scienc... Enobia Pharma, an emerging Canadia...apeutics for serious bone disorders, today announc...rogram for hypophosphatasia was dosed. Enobia is i... ENB-0040 for the treatment of this rare and often...
(Date:12/1/2008)... , , ROCHESTER, Minn., Dec. 1 /PRNewswire-...the use of the drug therapy etanercept ineffective...ation of the liver caused by excessive consumption...d in the December issue of Gastroenterology ( ht...LERT: Additional audio and video resources, includ...
(Date:12/1/2008)...swire-FirstCall/ -- Following a,Request for Propo...VA-based,third generation smallpox vaccine, Publ...f of the Canadian Department of National Defence, ... delivery of IMVAMUNE(R). , The Canadian au...,country,s bio-preparedness programme. , T...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3The impact of physical activity on weight bearing knee joint 2297 1The impact of physical activity on weight bearing knee joint 2297 2The impact of physical activity on weight bearing knee joint 2297 3Babies raised in bilingual homes learn new words differently than infants learning one language 2295 1Babies raised in bilingual homes learn new words differently than infants learning one language 2295 2Babies raised in bilingual homes learn new words differently than infants learning one language 2295 3Painful condition affecting kidney failure patients increases risk of death 2293 1Painful condition affecting kidney failure patients increases risk of death 2293 2Painful condition affecting kidney failure patients increases risk of death 2293 3APHA Urges President Bush Not To Veto CHIP 3B Were Only One Signature Away from Protecting the Health of Our Children 2291 1APHA Urges President Bush Not To Veto CHIP 3B Were Only One Signature Away from Protecting the Health of Our Children 2291 2
... WIRE)--Mar 26, 2007 - Inovio Biomedical Corp.,(AM...A vaccines and,a novel solid tumor ablation therap...s published a scientific paper prepared by,Inovio,...om a,non-human primate study of an investigational...omedical,s electroporation technology.,The paper, ...
...Outpatient Infusion Study in Patients with,Chronic...ican,College of Cardiology 56th Annual Scientific ... March 25, 2007,/PRNewswire/ -- Scios Inc. announc... study of nesiritide (NATRECOR(R)) showed a,neutra...eath and,cardiorenal hospitalization at 12 weeks, ...
Other Medicine Technology:Inovio Biomedical's DNA Delivery Technology Significantly Enhances,Potency of HIV DNA Vaccine 2Inovio Biomedical's DNA Delivery Technology Significantly Enhances,Potency of HIV DNA Vaccine 3Inovio Biomedical's DNA Delivery Technology Significantly Enhances,Potency of HIV DNA Vaccine 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7
...fely, the Hoefer GD 2000 uses a dry-heat vacuum me...through a heavy aluminum platen. , Dries acrylami...as thirty minutes., The heavy aluminum platen prov...bution under the gel., A clear silicone cover shee...
...ilizes a hot air drying device for polyacrylamide ...g frames at once. Gels are dried on a clear cellop...is recessed to provide a smooth, flat assembly sur...m includes a gel drying oven, 2 drying frames, 16 ...
The PRO6000 power supply is the latest edition to Thermo's power supply product offering. It sets new standards in proteomic and genomic electrophoresis. This product has unique features dedicated to
Capable of producing up to 500 volts and 500 milliamps, this power supply is ideal for PAGE, SDS-PAGE, DNA or RNA submarine gels as well as all types of small format transfer apparatus.
Medicine Products: